EXPERIMENTAL IMMUNOLOGY
Inhibition of adenovirus multiplication by inosine pranobex and interferon α in vitro
Submission date: 2015-05-23
Acceptance date: 2015-07-07
Publication date: 2016-01-15
Cent Eur J Immunol 2015;40(4):395-399
KEYWORDS
ABSTRACT
There are no specific antivirals designed for adenoviral infections. Due to many cases of adenovirus infections worldwide, epidemic nature of some types of adenoviruses, and growing number of patients with severe adenoviral infections resulting from dysfunction the immune system, the need for searching an effective and safe therapy is increasing. Inosine pranobex exerts antiviral effects which are both direct and secondary to immunomodulatory activity. In the present study we evaluated in vitro effect of inosine pranobex and interferon α (IFN-α) on replication of HAdV-2 and HAdV-5. The effectiveness of inosine pranobex under these conditions has not been previously reported. In conducted study we reported that inosine pranobex reduced the titer of infectious HAdV-2 and HAdV-5 in vitro. Higher concentrations of IP strongly inhibited multiplication of viruses. Combination of inosine pranobex and IFN-α display higher efficacy than either treatment alone and suggest that both agents may increase therapeutic effectiveness without augmenting toxic effects. Combination index calculations showed that inosine pranobex and INF-α synergistically inhibit HAdV-2 and HAdV-5 titers in A549 cells.
REFERENCES (26)
1.
Hoffman JA (2009): Adenovirus infections in solid organ transplant recipients. Curr Opin Organ Transplant 14: 625-633.
2.
Lenaerts L, Naesens L (2006): Antiviral therapy for adenovirus infections. Antiviral Res 71: 172-180.
3.
Tebruegge M, Curtis N (2010): Adenovirus infection in the immunocompromised host. Adv Exp Med Biol 659: 153-174.
4.
Hoke CH Jr, Snyder CE Jr (2013): History of the restoration of adenovirus type 4 and type 7 vaccine, live oral (Adenovirus Vaccine) in the context of the Department of Defense acquisition system. Vaccine 31: 1623-1632.
5.
Trojnar Z, Ciepiela O, Demkow UA (2014): The prevalence of IgG and IgA against adenoviruses in serum of children aged 11-26 months, hospitalised in the Clinical Paediatric Hospital in Warsaw Poland. Centr Eur J Immunol 39: 91-95.
6.
Anlar B, Aydin OF, Guven A, et al. (2004): Retrospective evaluation of interferon-beta treatment in subacute sclerosing panencephalitis. Clin Ther 26: 1890-1894.
7.
Mabley JG, Pacher P, Murthy KG, et al. (2008): The novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic mouse models of type I diabetes. J Endocrinol 198: 581-589.
8.
Kalliolias GD, Ivashkiv LB (2010): Overview of the biology of type I interferons. Arthritis Res Ther 12 Suppl 1: S1.
9.
Mohamed TA (2014): Validated analytical method development of inosine pranobex in drug products by thin layer chromatography. Science 2: 59-66.
10.
Schinazi RF, Cannon DL, Arnold BH, Martino-Saltzman D (1988): Combinations of isoprinosine and 3’-azido-3’-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother 32: 1784-1787.
11.
Drews JF (1990): Immunostimulation. In: Immunopharmacology: Principles and perspectives. Drews JF (ed.). Springer-Verlag and Heidelberg, GmbH & Co, Berlin; 201-285.
12.
Campoli-Richards DM, Sorkin EM, Heel RC (1986): Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 32: 383-424.
13.
Silvennoinen-Kassinen S, Karttunen R, Tiilikainen A, Huttunen K (1987): Isoprinosine enhances PHA responses and has potential effect on natural killer cell (NK) activity of uremic patients in vitro. Nephron 46: 243-246.
14.
Petrova M, Jelev D, Ivanova A, Krastev Z (2010): Isoprinosine affects serum cytokine levels in healthy adults. J Interferon Cytokine Res 30: 223-228.
15.
Lasek W, Janyst M, Wolny R, et al. (2015): Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes. Acta Pharm 65: 171-180.
16.
Gadoth N (2012): Subacute sclerosing panencephalitis (SSPE) the story of a vanishing disease. Brain Dev 34: 705-711.
17.
Gutierrez J, Issacson RS, Koppel BS (2010): Subacute sclerosing panencephalitis: an update. Dev Med Child Neurol 52: 901-907.
18.
Mossman KL, Saffran HA, Smiley JR (2000): Herpes simplex virus ICP0 mutants are hypersensitive to interferon. J Virol 74: 2052-2056.
19.
Pranczyk J, Jacewicz D, Wyrzykowski D, Chmurzynski L (2015): Platinum (II) and Palladium (II) Complex Compounds as Anti-cancer Drugs. Methods of Cytotoxicity Determination. Curr Pharm Anal 10: 2-9.
20.
Chow TC, Talalay PP (1984): Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
21.
De Clercq E (2002): Highlights in the development of new antiviral agents. Mini Rev Med Chem 2: 163-175.
22.
Kumar V, Chandra S, Siddiqi MI (2014): Recent advances in the development of antiviral agents using computer-aided structure based approaches. Curr Pharm Des 20: 3488-3199.
23.
Majewska A, Lasek W, Janyst M, Młynarczyk G (2016): In vitro inhibition of HHV-1 repication by inosine branobex and interferon-α. Acta Pol Pharm Drug Res 2 (accepted for publication).
24.
Mlynarczyk-Bonikowska B, Majewska A, Malejczyk M, et al. (2013): Antiviral medication in sexually transmitted diseases. Part I: HSV, HPV. Mini Rev Med Chem 13: 1837-1845.
25.
Majewska A, Mlynarczyk-Bonikowska B, Malejczyk M, et al. (2015): Antiviral medication in sexually transmitted diseases. Part II: HIV. Mini Rev Med Chem 15: 93-103.
26.
De Clercq E (2013): Dancing with chemical formulae of antivirals: A panoramic view (Part 2). Biochem Pharmacol 15: 1397-1410.
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
